No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
cetuximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
cisplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
5-fluorouracil + mitomycin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
carboplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
cisplatin + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
imiquimod
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Penile Cancer
Penile Cancer
|
TIP
Sensitive: A2 - Guideline
|
|
Penile Cancer
Penile Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
|
Penile Cancer
Penile Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Penile Cancer
Penile Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
TMB-H + PD-L1 expression + MSI-L/dMMR
TMB-H + PD-L1 expression + MSI-L/dMMR
|
Penile Cancer
Penile Cancer
|
nivolumab + ipilimumab
Sensitive: C4 – Case Studies
|
TMB-H + PD-L1 expression
TMB-H + PD-L1 expression
|
Penile Cancer
Penile Cancer
|
toripalimab
Sensitive: C4 – Case Studies
|
CDKN2A mutation
CDKN2A mutation
|
Penile Cancer
Penile Cancer
|
nivolumab
Sensitive: C4 – Case Studies
|
